D-1325-2022 Class II Terminated
FDA drug recall D-1325-2022 was initiated by Mckesson Medical-Surgical Inc. Corporate Office on Jun 29, 2022 and is designated Class II. Reason for recall: CGMP Deviations: products were stored outside the drug label specifications. The recall status is terminated (terminated Feb 13, 2024). Affected quantity: 23 cartons.
Recall Details
- Product Type
- Drugs
- Report Date
- Aug 17, 2022
- Initiation Date
- Jun 29, 2022
- Termination Date
- Feb 13, 2024
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 23 cartons
Product Description
Racepinephrine Inhalation Solution, USP 2.25%, Bronchodilator, For Oral Inhalation Only, Sulfite Free, Preservative Free, 30 x 0.5 mL Sterile Unit-of-Use Vials, each in a foil pouch, per carton, Nephron Pharmaceuticals Corporation, NDC 0487-5901-99.
Reason for Recall
CGMP Deviations: products were stored outside the drug label specifications.
Distribution Pattern
Nationwide in the USA.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1325-2022
- openFDA file date
- Oct 23, 2026
- Loaded by RegDataLab
- Oct 25, 2026